Recombinant Cyclin-Dependent Kinase Inhibitor 2A (rHuP16-INK4a)
Cyclin-dependent kinase inhibitors (CDKIs) are proteins that bind to and inhibit the activity of CDKs. Two major classes of CDK inhibitors have been identified. The p16 family (p15, p16, p18 and p19) binds to and inhibits the activities of CDK4 and CDK6. The p21 family (p21, p27, p28 and p57) can bind to broad range of CDK-cyclin complexes and inhibit their activities. CDKIs are capable of suppressing growth, and several lines of evidence strongly suggest that at least some CDKIs may be tumor suppressor proteins.
Product Specifications
Source
Escherichia coli
Field of Research
Pharmacology & Drug Discovery; Cell Biology
Endotoxin
Less than 1EU/mg of rHuP16 as determined by LAL method.
Purity
>95% by SDS-PAGE and HPLC analyses.
Bioactivity
Data Not Available.
Form
Lyophilized from a 0.2mm filtered concentrated solution in PBS, pH 7.4.
Molecular Weight
Approximately 16.5 kDa, a single non-glycosylated polypeptide chain containing 156 amino acids.
Storage Conditions
Notes
For research use only.
Applications Notes
Preservative
Lyophilized from a 0.2mm filtered concentrated solution in PBS, pH 7.4.
AA Sequence
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Pmel17 / gp100 / SILV (NKI-beteb), CF568 conjugate, 0.1mg/mL
Mucin 5AC (MUC5AC) (45M1), CF405S conjugate, 0.1mg/mL
MAGE A1 (MZ2E/838), CF488A conjugate, 0.1mg/mL
Cytokeratin 4 (KRT4) (KRT4/2804), CF640R conjugate, 0.1mg/mL
